New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus
New data from Mayo Clinic researchers presented at DDW 2026 demonstrates that Castle Biosciences' TissueCypher test improves risk stratification for Barrett's esophagus compared to standard histopathology. One study found physicians modified surveillance intervals in 55% of patients based on TissueCypher results, while a second study showed the test classified 84% of patients as low risk versus just 38% for the standard PIB model.
Key figures
- Patients studied
- 8000
- Pib low risk pct
- 38
- Pib concordance kappa
- 0.04
- Tissuecypher low risk pct
- 84
- Peer reviewed publications
- 17
- Risk classification alignment pct
- 79
- Surveillance intervals modified pct
- 55
- Intermediate high risk shorter interval pct
- 93
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.